Recovering scientist turned early stage VC A biotech optimist fighting gravity

Company Profile Considerations in A Conservative Cash Environment
October 18, 2023

By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC As we enter the final leg of 2023, navigating the investment market in biotech continues to be fraught with twists and turns. The

Leave a comment

My Love/Hate Relationship with Process
October 5, 2023

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I remember vividly my first vacation with the man who would be my husband.  In the days before Airbnb and on-line travel websites, he

Leave a comment

Smooth Transitions: Planning For CEO And Board Succession
September 28, 2023

By Ankit Mahadevia, Chairman of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Nobody stays in a particular role forever. While change at the senior level can be disruptive, it doesn’t have to be. Teams and

Leave a comment

Growth Mindset for the “Crystallized Intellect”
August 30, 2023

More Musings from an Old CEO By Natalie Holles, CEO of Third Harmonic Bio, as part of the From The Trenches feature of LifeSciVC The only way we grow as leaders is by stretching the limits of who we are

Leave a comment

On the Road at ASCO 2023: Key Takeaways, Observations and Reflections
July 11, 2023

By Amanda J. Redig, SVP and Head of Clinical Development at HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology

Leave a comment

The Opportunities Waiting on Big Pharma Shelves
July 6, 2023

By Mike Cloonan, CEO of Sionna Therapeutics In 2016, following robust discovery efforts by Pfizer and others, the NBD1 domain of the CFTR protein was largely considered undruggable. They knew it was a key target – the most common genetic

Leave a comment

It’s a Wonderful Banking Life
June 13, 2023

By Robert Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC It’s now been a couple of months since the SVB collapse and the scramble many of us faced during that tumultuous few weeks.

Leave a comment

Hybrid model update: Did we get it right?  
May 31, 2023

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC This time a quarter ago organizations large and small were in the thick of the “to hybrid or not to hybrid” debate. Each

Leave a comment

The Book of Nimbus
April 27, 2023

By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC Forward Nimbus Therapeutics began 14 years ago.  The premise at the time was that putting computational chemistry in the primary position for new

Leave a comment

Biotech Funding: Times Are Tough, Maybe For The Better
April 14, 2023

Times remain tough for private biotech venture capital funding. Access to capital is more constrained than it’s been in years, and companies are starting to feel the pinch.  Yet, despite the pain after a cycle of excess, perhaps this return

Leave a comment

The Oscar for Making Payroll Goes to…..
March 21, 2023

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC It was the last thing our finance team needed; a vague email from the CEO on a Thursday afternoon.  They were working on the

Leave a comment

A Diverse Culture From The Beginning At Early-Stage Biotechs
March 20, 2023

By Mike Cloonan, CEO of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC There are a lot of reasons to be excited about leading an early-stage biotech company. It’s a chance to be at the forefront

Leave a comment